HUDDINGE, Sweden--(BUSINESS WIRE)-- Regulatory News:
The number of shares and votes in Medivir (STO:MVIRB) has changed as a result of the exercise of employee stock options.
Today, the last trading day of the month, there are in total 31,244,606 shares and 37,184,606 votes in the company.
Medivir is an emerging research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is TMC435, a novel protease inhibitor is in phase 3 clinical development for hepatitis C and is partnered with Tibotec Pharmaceuticals. In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia to ensure timely commercialization of TMC435 in the Nordic markets, once approved.
Medivir’s first product, the unique cold sore product Xerese™/Xerclear® was launched on the US market in February 2011. Xerese™/Xerclear®, which has been approved in both the US and Europe is partnered with GlaxoSmithKline to be sold OTC in Europe, Japan and Russia. Rights in North America, Canada and Mexico have recently been sold to Meda AB. Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.
For more information about Medivir, please visit the Company’s website: www.medivir.com.
This information was brought to you by Cision http://www.cisionwire.com
Rein Piir, CFO and VP, Investor Relations, -468708-537 292
KEYWORDS: Europe Sweden
INDUSTRY KEYWORDS: Health Pharmaceutical Research Science